{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:02:52Z","timestamp":1789729372779,"version":"4.0.1"},"reference-count":54,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2013,3,11]],"date-time":"2013-03-11T00:00:00Z","timestamp":1362960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Vitamin D has reported anti-cancer and anti-inflammatory properties modulated through gene transcription and non-genomic signaling cascades. The purpose of this review was to summarize the available research on interactions and pharmacokinetics between vitamin D and the pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high dose calcitriol. The half-life of 25(OH)D3 and\/or 1,25(OH)2D3 was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs. No unusual adverse effects in cancer patients; beyond what is expected from high dose 1,25(OH)2D3 supplementation, were revealed through this review. While sufficient evidence is lacking, supplementation with 1,25(OH)2D3 during chemotherapy appears to have a low risk of interaction. Further interactions with vitamin D3 have not been studied.<\/jats:p>","DOI":"10.3390\/cancers5010255","type":"journal-article","created":{"date-parts":[[2013,3,11]],"date-time":"2013-03-11T12:14:24Z","timestamp":1363004064000},"page":"255-280","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Vitamin D: Pharmacokinetics and Safety When Used in Conjunction with the Pharmaceutical Drugs Used in Cancer Patients: A Systematic Review"],"prefix":"10.3390","volume":"5","author":[{"given":"Deborah","family":"Kennedy","sequence":"first","affiliation":[{"name":"Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario,  M2K 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7960-6504","authenticated-orcid":false,"given":"Kieran","family":"Cooley","sequence":"additional","affiliation":[{"name":"Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario,  M2K 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Skidmore","sequence":"additional","affiliation":[{"name":"Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario,  M2K 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Fritz","sequence":"additional","affiliation":[{"name":"Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario,  M2K 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Campbell","sequence":"additional","affiliation":[{"name":"Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario,  M2K 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dugald","family":"Seely","sequence":"additional","affiliation":[{"name":"Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario,  M2K 1E2, Canada"},{"name":"Ottawa Integrative Cancer Centre, 29 Bayswater Avenue, Ottawa, Ontario, K1Y 2E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2013,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCOUTCOMES.112.967604","article-title":"Circulating 25-hydroxy-vitamin d and risk of cardiovascular disease: A meta-analysis of prospective studies","volume":"5","author":"Wang","year":"2012","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.beem.2011.05.001","article-title":"The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3","volume":"25","author":"Vanoirbeek","year":"2011","journal-title":"Baillieres Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lang, P.O., Samaras, N., Samaras, D., and Aspinall, R. (2012). How important is vitamin D in preventing infections?. Osteoporos. Int.","DOI":"10.1007\/s00198-012-2204-6"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Schottker, B., Ball, D., Gellert, C., and Brenner, H. (2012). Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res. Rev.","DOI":"10.1016\/j.arr.2012.02.004"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Plum, L., and DeLuca, H. (2010). The Functional metabolism and molecular biology of vitamin D action, Humana Press. [2nd].","DOI":"10.1007\/978-1-60327-303-9_3"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MNH.0b013e328346d6ba","article-title":"Determinants of vitamin D status: Focus on genetic variations","volume":"20","author":"Berry","year":"2011","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1111\/j.1753-4887.2008.00105.x","article-title":"Evolution of our understanding of vitamin D","volume":"66","author":"DeLuca","year":"2008","journal-title":"Nutr. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0169-6009(90)90023-9","article-title":"The mechanisms of vitamin D toxicity","volume":"11","author":"Vieth","year":"1990","journal-title":"Bone Miner."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"582S","DOI":"10.1093\/ajcn\/88.2.582S","article-title":"Pharmacokinetics of vitamin D toxicity","volume":"88","author":"Jones","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"d2040","DOI":"10.1136\/bmj.d2040","article-title":"Calcium supplements with or without vitamin D and risk of cardiovascular events: Reanalysis of the Women's Health Initiative limited access dataset and meta-analysis","volume":"342","author":"Bolland","year":"2011","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ajcn\/85.6.1586","article-title":"Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial","volume":"85","author":"Lappe","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1210\/jc.2012-1451","article-title":"Vitamin D3 supplementation at 4,000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance","volume":"97","author":"Marshall","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10552-011-9885-6","article-title":"Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: A population-based study","volume":"23","author":"Tretli","year":"2012","journal-title":"Cancer Causes Control"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2011.01.023","article-title":"Meta-analysis: Circulating vitamin D and ovarian cancer risk","volume":"121","author":"Yin","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.ejca.2010.03.037","article-title":"Meta-analysis: Serum vitamin D and breast cancer risk","volume":"46","author":"Yin","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2036.2009.04022.x","article-title":"Meta-analysis: Longitudinal studies of serum vitamin D and colorectal cancer risk","volume":"30","author":"Yin","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PPO.0b013e3181c51ee6","article-title":"Vitamin D: Considerations in the continued development as an agent for cancer prevention and therapy","volume":"16","author":"Trump","year":"2010","journal-title":"Cancer J."},{"key":"ref_19","first-page":"96","article-title":"Symptomatic hypercalcemia after vitamin D-thiazide diuretics combination. Two cases in elderly women","volume":"23","author":"Boulard","year":"1994","journal-title":"Presse Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V63.3.639.639","article-title":"Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma","volume":"63","author":"Cohen","year":"1984","journal-title":"Blood"},{"key":"ref_21","first-page":"3605","article-title":"A phase II trial of calcitriol and naproxen in recurrent prostate cancer","volume":"29","author":"Srinivas","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/jco.2003.05.117","article-title":"Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer","volume":"21","author":"Beer","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1158\/1078-0432.CCR-06-1165","article-title":"A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors","volume":"13","author":"Fakih","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jsbmb.2004.03.068","article-title":"Anti-tumor activity of calcitriol: Pre-clinical and clinical studies","volume":"89\u201390","author":"Trump","year":"2004","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000076336","article-title":"Pharmacokinetics of 1\u03b1,25-Dihydroxyvitamin D3 in Normal Mice after Systemic Exposure to Effective and Safe Antitumor Doses","volume":"66","author":"Muindi","year":"2004","journal-title":"Oncology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00280-009-1000-2","article-title":"A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors","volume":"65","author":"Muindi","year":"2009","journal-title":"Cancer Chemother. Pharmacol"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1464-410X.2007.07019.x","article-title":"Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel","volume":"100","author":"Petrioli","year":"2007","journal-title":"BJU Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000169261.42298.e6","article-title":"High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: A phase I\/II study","volume":"174","author":"Tiffany","year":"2005","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1210\/jcem-28-9-1341","article-title":"Effects of prednisone on vitamin D metabolism in man","volume":"28","author":"Avioli","year":"1968","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1067\/mcp.2002.129305","article-title":"Pharmacokinetics of high-dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel","volume":"72","author":"Muindi","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10557-009-6181-8","article-title":"Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: A novel pleiotropic effect of statins?","volume":"23","author":"Yavuz","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1755-5922.2010.00141.x","article-title":"STATIN-D Study: Comparison of the Influences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin D","volume":"29","author":"Ertugrul","year":"2011","journal-title":"Cardiovasc. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000200333","article-title":"Effect of cimetidine on hepatic vitamin D metabolism in humans","volume":"46","author":"Odes","year":"1990","journal-title":"Digestion"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1507\/endocrj.40.737","article-title":"The effects of chemotherapy including cisplatin on vitamin D metabolism","volume":"40","author":"Gao","year":"1993","journal-title":"Endocr. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00384-008-0593-y","article-title":"Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer","volume":"24","author":"Fakih","year":"2009","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10549-012-2084-7","article-title":"Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy","volume":"2","author":"Jacot","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_37","unstructured":"Feldman, D., Pike, J.W.S., and Adams, J. (2011). Vitamin D, Elsevier Science & Technology Books. [3rd]."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-0760(03)00063-3","article-title":"Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells","volume":"84","author":"Farhan","year":"2003","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/mol.111.076356","article-title":"An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway","volume":"81","author":"Wang","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"ref_40","unstructured":"International Clinical Trials Search Portal: Registry Platform. Version 3.2. Available online:http:\/\/apps.who.int\/trialsearch\/."},{"key":"ref_41","unstructured":"metaRegister of Controlled Trials (mRCT). Available online:http:\/\/www.controlled-trials.com\/mrct\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jclinepi.2008.10.012","article-title":"An evidence-based practice guideline for the peer review of electronic search strategies","volume":"62","author":"Sampson","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-0609.1988.tb00855.x","article-title":"Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin d3 and retinoic acid in acute leukemia and myelodysplastic syndromes","volume":"40","author":"Hellstrom","year":"1988","journal-title":"Eur. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.2830410307","article-title":"Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol","volume":"41","author":"Slapak","year":"1992","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/jco.2003.05.117","article-title":"Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer","volume":"21","author":"Beer","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.coc.0000136020.27904.9c","article-title":"High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer","volume":"27","author":"Beer","year":"2004","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/cncr.20185","article-title":"High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma","volume":"100","author":"Morris","year":"2004","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.21890","article-title":"Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin d3) and dexamethasone in androgen-independent prostate cancer","volume":"106","author":"Trump","year":"2006","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ascent investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1464-410X.2008.08017.x","article-title":"A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer","volume":"102","author":"Chan","year":"2008","journal-title":"BJU Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cncr.23163","article-title":"Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ascent, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel","volume":"112","author":"Beer","year":"2008","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s10637-008-9184-6","article-title":"Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer","volume":"27","author":"Blanke","year":"2009","journal-title":"Invest. New Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/cncr.24973","article-title":"Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer","volume":"116","author":"Chadha","year":"2010","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2010.32.8815","article-title":"Randomized, open-label phase iii trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer","volume":"29","author":"Scher","year":"2011","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/5\/1\/255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:45:27Z","timestamp":1760219127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/5\/1\/255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,3]]}},"alternative-id":["cancers5010255"],"URL":"https:\/\/doi.org\/10.3390\/cancers5010255","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,11]]}}}